CN104758827B - A kind of composition of medicine for being used to treat acute viral hepatitis - Google Patents
A kind of composition of medicine for being used to treat acute viral hepatitis Download PDFInfo
- Publication number
- CN104758827B CN104758827B CN201510137276.9A CN201510137276A CN104758827B CN 104758827 B CN104758827 B CN 104758827B CN 201510137276 A CN201510137276 A CN 201510137276A CN 104758827 B CN104758827 B CN 104758827B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- extract
- medicine
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 206010019799 Hepatitis viral Diseases 0.000 title claims abstract description 15
- 230000001154 acute effect Effects 0.000 title claims abstract description 15
- 201000001862 viral hepatitis Diseases 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims description 9
- 239000000284 extract Substances 0.000 claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000002829 reductive effect Effects 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 10
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 10
- 230000000717 retained effect Effects 0.000 claims abstract description 10
- 240000008042 Zea mays Species 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 8
- 241000522190 Desmodium Species 0.000 claims abstract description 6
- 229920002472 Starch Polymers 0.000 claims abstract description 6
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 239000008107 starch Substances 0.000 claims abstract description 6
- 235000019698 starch Nutrition 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000004375 Dextrin Substances 0.000 claims abstract description 3
- 229920001353 Dextrin Polymers 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 235000019425 dextrin Nutrition 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 3
- 240000004980 Rheum officinale Species 0.000 claims 2
- 235000008081 Rheum officinale Nutrition 0.000 claims 2
- 240000007651 Rubus glaucus Species 0.000 claims 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 2
- 235000005822 corn Nutrition 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 238000009835 boiling Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 238000002386 leaching Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract description 11
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 10
- 229960001997 adefovir Drugs 0.000 abstract description 10
- 229940010454 licorice Drugs 0.000 abstract description 10
- 241000092665 Atractylodes macrocephala Species 0.000 abstract description 8
- 244000235659 Rubus idaeus Species 0.000 abstract description 8
- 244000163122 Curcuma domestica Species 0.000 abstract description 7
- 235000007244 Zea mays Nutrition 0.000 abstract description 7
- 229940089639 cornsilk Drugs 0.000 abstract description 7
- 239000001231 zea mays silk Substances 0.000 abstract description 7
- 239000008187 granular material Substances 0.000 abstract description 5
- 239000012141 concentrate Substances 0.000 abstract description 3
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 239000010072 ban-zhi-lian Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 206010023126 Jaundice Diseases 0.000 description 15
- 241000219061 Rheum Species 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 241000555712 Forsythia Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 235000003392 Curcuma domestica Nutrition 0.000 description 6
- 241000202807 Glycyrrhiza Species 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 235000003373 curcuma longa Nutrition 0.000 description 6
- 235000013976 turmeric Nutrition 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000915604 Scutellaria barbata Species 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- LPLVUJXQOOQHMX-MOGLOQIBSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-MOGLOQIBSA-N 0.000 description 1
- -1 18α glycyrrhizic acid diamine salt Chemical class 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗急性病毒性肝炎的组合药物,包括以下重量份的原料药:阿德福韦0.01‑0.02份、大黄15‑20份、甘草15‑20份、连翘15‑20份、白术15‑20份、金钱草15‑20份、半枝莲15‑20份、郁金15‑20份、覆盆子15‑20份、玉米须15‑20份。该组合药物的制备方法为:首先将原料药材,用10倍重量的80%乙醇回流提取,提取2小时,过滤,药渣保留,收集乙醇提取液,减压回收乙醇后,进一步浓缩至稠膏,真空或微波干燥,得到干浸膏;再向药渣加8倍重量的水煎煮提取2次,每次1.5~2小时,过滤,合并水提液,减压浓缩至稠膏,真空或微波干燥,得到干浸膏;合并所得的浸膏,粉碎,加入阿德福韦,再加入淀粉或糊精混合均匀,制成片剂、颗粒或胶囊剂,分装即得。The invention discloses a combined medicine for treating acute viral hepatitis, which comprises the following raw materials in parts by weight: 0.01-0.02 parts of adefovir, 15-20 parts of rhubarb, 15-20 parts of licorice, and 15-20 parts of forsythia 20 parts, 15‑20 parts of Atractylodes macrocephala, 15‑20 parts of Desmodium, 15‑20 parts of Banzhilian, 15‑20 parts of Curcuma, 15‑20 parts of raspberry, 15‑20 parts of corn silk. The preparation method of the combined medicine is as follows: firstly, the raw medicinal material is extracted with 10 times the weight of 80% ethanol under reflux, extracted for 2 hours, filtered, the dregs are retained, the ethanol extract is collected, and the ethanol is recovered under reduced pressure, and then further concentrated to a thick paste , vacuum or microwave drying to obtain a dry extract; then add 8 times the weight of water to the dregs to decoct and extract twice, each time for 1.5 to 2 hours, filter, combine the water extracts, concentrate under reduced pressure to a thick paste, vacuum or Microwave drying to obtain dry extracts; combine the obtained extracts, crush them, add adefovir, and then add starch or dextrin to mix evenly, make tablets, granules or capsules, and pack them separately.
Description
技术领域technical field
本发明涉及一种组合药物,尤其涉及一种用于治疗急性病毒性肝炎的组合药物。The invention relates to a combined medicine, in particular to a combined medicine for treating acute viral hepatitis.
背景技术Background technique
急性病毒性肝炎是指由特异的嗜肝细胞病毒引起的广泛的肝脏炎症性疾病,潜伏期在15~45天之间,平均25天,总病程2~4个月。有甲、乙、丙、丁、戊五型,甲与戊为潜伏期较短的急性肝炎。病毒性肝炎的主要症状为乏力、食欲不振、肝功能异常,部分病人可有发热及黄疽等,有的病程迁延或反复发作成为慢性;少数人发展成为重症肝炎。重症肝炎病情凶险,死亡率高。死亡原因主要为肝昏迷、肝功能衰竭、电解质紊乱及继发性感染。各型肝炎之间无交叉免疫,可同时或先后感染,混合感染或重叠感染,使症状加重。甲型病毒性肝炎和戊型病毒性肝炎以粪一口传播为主,常见发热、黄疽,呈急性经过,罕见迁延成慢性。Acute viral hepatitis refers to a wide range of liver inflammatory diseases caused by specific hepatotropic viruses. The incubation period is between 15 and 45 days, with an average of 25 days, and the total course of disease is 2 to 4 months. There are five types of hepatitis A, B, C, D, and E, and A and E are acute hepatitis with a short incubation period. The main symptoms of viral hepatitis are fatigue, loss of appetite, and abnormal liver function. Some patients may have fever and jaundice. Severe hepatitis is dangerous and has a high mortality rate. The main causes of death were hepatic coma, liver failure, electrolyte disturbance and secondary infection. There is no cross-immunity between various types of hepatitis, and they can be infected simultaneously or successively, mixed infection or overlapping infection, which aggravates the symptoms. Viral hepatitis A and viral hepatitis E are mainly transmitted by feces. Fever and jaundice are common, with an acute course and rare protracted chronicity.
现在对急性病毒性肝炎的常规治疗是:前期抗病毒治疗,主要药物是干扰素和拉米夫定等,后期加入护肝药物,结合治疗。在现实的治疗中,抗病毒的药物都具有很强的副作用和耐药性,同时还会对患者的肾功能造成伤害。The current conventional treatment for acute viral hepatitis is: antiviral treatment in the early stage, the main drugs are interferon and lamivudine, etc., and liver-protecting drugs are added in the later stage, combined with treatment. In actual treatment, antiviral drugs have strong side effects and drug resistance, and will also cause damage to the patient's renal function.
发明内容Contents of the invention
本发明的目的是提供一种用于治疗急性病毒性肝炎的组合药物。The object of the present invention is to provide a combination medicine for treating acute viral hepatitis.
根据急性病毒性肝炎的病机和发病特点,本发明提供一种中西医结合治疗的组合药物:低剂量的抗病毒药物,结合中药,协同治疗。According to the pathogenesis and pathogenesis characteristics of acute viral hepatitis, the invention provides a combined drug for the treatment of integrated traditional Chinese and western medicine: low-dose antiviral drug, combined with traditional Chinese medicine, for synergistic treatment.
其中,阿德福韦起到主要的抗病毒作用,经细胞内激酶磷酸化形成有活性的二磷酸盐,竞争抑制HBV DNA多聚酶,从而抑制病毒的复制。Among them, adefovir plays a major antiviral role. It is phosphorylated by intracellular kinases to form active diphosphates, which competes to inhibit HBV DNA polymerase, thereby inhibiting virus replication.
本发明所述的中药各组分功效如下:Each component effect of Chinese medicine of the present invention is as follows:
大黄:味苦,性寒,归脾、胃、大肠、肝、心包经,泻热通肠,凉血解毒,逐瘀通经。用于实热便秘,积滞腹痛,泻痢不爽,湿热黄疸。现代药理研究表明,大黄醇提取液可抑制病毒的复制,对HBsAg具有直接的灭活作用,并提出大黄具有直接杀伤病毒的作用。大黄蒽醌类可与DN A相结合,抑制DN A、RN A和蛋白质的生物合成,从而抑制细菌、病毒的复制。部分研究者认为大黄具有增强细胞免疫,抑制体液免疫的作用,能抑制单核巨噬细胞的过度激活,减少TNF、IL-6、IL-1等细胞因子的释放,诱导体内干扰素的产生而发挥抗HBV的作用。Rhubarb: Bitter in taste, cold in nature, returns to the spleen, stomach, large intestine, liver, and pericardium meridian, relieves heat and unblocks the intestines, cools blood and detoxifies, expels blood stasis and stimulates menstrual flow. For excess heat constipation, stagnant abdominal pain, dysentery, jaundice due to damp heat. Modern pharmacological studies have shown that rhubarb alcohol extract can inhibit the replication of viruses and have a direct inactivation effect on HBsAg, and it is proposed that rhubarb has a direct virus-killing effect. Rhubarb anthraquinones can combine with DNA to inhibit the biosynthesis of DNA, RNA and protein, thereby inhibiting the replication of bacteria and viruses. Some researchers believe that rhubarb has the effect of enhancing cellular immunity and inhibiting humoral immunity, can inhibit the excessive activation of monocytes and macrophages, reduce the release of TNF, IL-6, IL-1 and other cytokines, and induce the production of interferon in vivo. Play the role of anti-HBV.
甘草:甘,平。归经:归心、肺、脾、胃经。主治补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。甘草里含有甘草酸等有效成分,能通过抑制补体而防止肝细胞损害,进而起到保肝的作用。此外,它还能集中附着在肝细胞内抑制乙肝病毒。甘草具有皮质激素样的抗炎作用,抗炎成分为甘草甜素和甘草次酸,能恢复肝功能,降低ALT的活力,以及对乙型肝炎表面抗原及e抗原的抑制作用。其中甘草中含有的18α甘草酸二胺盐,具有较强的抗炎、保护肝细胞膜与降酶快,抑制肝细胞坏死,促进肝细胞再生改善肝功能等作用。Licorice: sweet, flat. Meridian distribution: Guixin, lung, spleen, stomach meridians. Cure mainly invigorating the spleen and replenishing qi, clearing heat and detoxifying, eliminating phlegm and relieving cough, relieving spasm and relieving pain, coordinating various medicines. Licorice contains active ingredients such as glycyrrhizic acid, which can prevent liver cell damage by inhibiting complement, thereby protecting the liver. In addition, it can also concentrate in the liver cells to inhibit hepatitis B virus. Licorice has corticosteroid-like anti-inflammatory effects. The anti-inflammatory components are glycyrrhizin and glycyrrhetinic acid, which can restore liver function, reduce ALT activity, and inhibit hepatitis B surface antigen and e antigen. Among them, 18α glycyrrhizic acid diamine salt contained in licorice has strong anti-inflammation, protection of liver cell membrane and rapid enzyme reduction, inhibition of liver cell necrosis, promotion of liver cell regeneration and improvement of liver function.
连翘:苦,凉,入心、肝、胆经,清热,解毒,散结,消肿。现代药理研究表明,连翘具有明显的降低转氨酶作用,连翘中含有齐墩果酸和熊果酸,齐墩果酸对急慢性肝损伤有明显保护作用,可以使肿大的线粒体与扩张的粗面内质网得到恢复;还可使急性和慢性肝损伤的肝细胞气球样变性、坏死和炎性反应明显减轻,促进肝细胞的再生;熊果酸具有降低转氨酶的作用。Forsythia: bitter, cool, enters the heart, liver, and gallbladder meridian, clears away heat, detoxifies, dissipates stagnation, and reduces swelling. Modern pharmacological studies have shown that forsythia can significantly reduce transaminases. Forsythia contains oleanolic acid and ursolic acid. Oleanolic acid has obvious protective effects on acute and chronic liver damage, and can make enlarged mitochondria and expanded The rough endoplasmic reticulum is restored; it can also significantly reduce the ballooning degeneration, necrosis and inflammatory response of hepatocytes in acute and chronic liver injury, and promote the regeneration of liver cells; ursolic acid has the effect of reducing transaminase.
白术:味苦,甘,性温。归脾、胃经,健脾益气,燥湿利水。白术有补脾燥湿的作用,故可用于脾胃虚弱、食少倦怠及脾虚湿困、腹胀泄泻等症,现代药理研究表明,白术水煎剂对小鼠四氯化碳所致肝损伤具有保护作用。Atractylodes macrocephala: bitter in the mouth, sweet, warm in nature. Return spleen, stomach meridian, invigorate the spleen and replenish qi, dry damp and promote diuresis. Atractylodes macrocephala has the effect of invigorating the spleen and drying dampness, so it can be used for weak spleen and stomach, lack of food, fatigue, spleen deficiency and dampness, abdominal distension and diarrhea. Protective effects.
金钱草:味甘、微苦,性凉。归肝、胆、肾、膀胱经。利水通淋;清热解毒;散瘀消肿。主治肝胆及泌尿系结石;湿热黄疸;清热利水通淋,除湿退黄,解毒;用于湿热黄胆。本品又能清热利湿,利疸退黄,用于湿热黄疸。Desmodium: sweet, slightly bitter, cool in nature. Return liver, gallbladder, kidney, urinary bladder channel. Inducing diuresis to relieve stranguria; heat-clearing and toxic substances removing; dispelling blood stasis and reducing swelling. Indications for liver and gallbladder and urinary calculus; damp-heat jaundice; clearing away heat and diuresis to treat stranguria, dehumidification and jaundice, detoxification; used for damp-heat jaundice. This product can clear heat and dampness again, promote jaundice and reduce jaundice, and is used for damp-heat jaundice.
半枝莲:味辛、苦,性寒。清热解毒,化瘀利尿。用于疔疮肿毒,咽喉肿痛,跌扑伤痛,水肿,黄疸。Scutellaria barbata: spicy, bitter, cold in nature. Heat-clearing and toxic substances removing, removing blood stasis and inducing diuresis. For furuncle swelling, sore throat, tumbling pain, edema, jaundice.
郁金:辛、苦,寒。活血止痛,行气解郁,清心凉血,利胆退黄。用于胸胁刺痛,胸痹心痛,经闭痛经,乳房胀痛,热病神昏,癫痫发狂,血热吐衄,黄疸尿赤;现代药理研究表明郁金具有改善微循环,促进受损肝细胞的再生与修复。Radix Curcumae: pungent, bitter, cold. Promoting blood circulation to relieve pain, promoting qi circulation and relieving depression, clearing away heart-fire and cooling blood, promoting gallbladder and reducing jaundice. It is used for chest and hypochondrium tingling pain, chest obstruction and heart pain, amenorrhea dysmenorrhea, breast distending pain, febrile coma, epilepsy and madness, blood heat vomiting, jaundice and red urine; modern pharmacological studies have shown that turmeric can improve microcirculation and promote damaged blood circulation. Liver cell regeneration and repair.
覆盆子:性味:味甘、酸,性温,归肝、肾、膀胱经,益肾固精缩尿,养肝明目。现代药理研究表明,覆盆子具有增强人体免疫功能在作用。Raspberry: Nature and flavor: sweet, sour, warm in nature, returns to the liver, kidney, and bladder meridians, nourishes the kidney, strengthens essence and reduces urination, nourishes the liver and improves eyesight. Modern pharmacological research shows that raspberry has the function of enhancing human immune function.
玉米须:味甘性平,有利尿消肿、降血压、止血、利胆等作用。本品甘淡而平,功能利水渗湿消肿作用,能使肝胆湿热从小便出,利疸退黄,用于治疗湿热黄疸。Corn silk: sweet and neutral in taste, diuretic, swelling, lowering blood pressure, hemostasis, choleretic and other effects. This product is sweet, light and flat, and has the function of diuresis, dampness and swelling, and can make the liver and gallbladder damp-heat come out from urine, promote jaundice and reduce jaundice, and is used to treat damp-heat jaundice.
本发明的目的是通过以下技术方案来实现的:The purpose of the present invention is achieved through the following technical solutions:
本发明的一种用于治疗急性病毒性肝炎的组合药物,其特征在于,其组分为以下原料药按重量份组成:阿德福韦0.01-0.02份、大黄15-20份、甘草15-20份、连翘15-20份、白术15-20份、金钱草15-20份、半枝莲15-20份、郁金15-20份、覆盆子15-20份、玉米须15-20份。A combination medicine for treating acute viral hepatitis of the present invention is characterized in that its components are composed of the following raw materials in parts by weight: 0.01-0.02 parts of adefovir, 15-20 parts of rhubarb, 15-20 parts of licorice 20 parts, 15-20 parts of forsythia, 15-20 parts of Atractylodes macrocephala, 15-20 parts of money grass, 15-20 parts of Scutellaria barbata, 15-20 parts of turmeric, 15-20 parts of raspberry, 15-20 parts of corn silk share.
本发明所述的药物的制备方法包括以下步骤The preparation method of medicine described in the present invention comprises the following steps
(1)按重量份计,将原料中药材,用10倍量的80%乙醇回流提取,提取2小时,过滤,药渣保留,收集乙醇提取液,减压回收乙醇后,进一步浓缩至稠膏,真空或微波干燥,得到干浸膏;(1) In parts by weight, the raw Chinese medicinal materials are reflux extracted with 10 times the amount of 80% ethanol, extracted for 2 hours, filtered, the dregs are retained, the ethanol extract is collected, and after the ethanol is recovered under reduced pressure, it is further concentrated to a thick paste , vacuum or microwave drying to obtain dry extract;
(2)将(1)步骤中保留的药渣加8倍量的水煎煮提取2次,每次1.5~2小时,过滤,合并水提液,减压浓缩至稠膏,真空或微波干燥,得到干浸膏;(2) Add 8 times the amount of water to decoct the medicinal residues retained in (1) to extract twice, each time for 1.5 to 2 hours, filter, combine the water extracts, concentrate under reduced pressure to a thick paste, and dry in vacuum or microwave , to obtain dry extract;
(3)将(1)和(2)步骤中所得的浸膏合并,粉碎,加入阿德福韦,再加入淀粉或糊精混合均匀,制成片剂、颗粒或胶囊剂,分装即得。(3) Combine the extracts obtained in steps (1) and (2), crush them, add adefovir, then add starch or dextrin and mix evenly, make tablets, granules or capsules, and pack them separately. .
治疗急性病毒性肝炎的组合药物的每日剂量约为0.008克和80克原药材。The daily dosage of the combined drug for treating acute viral hepatitis is about 0.008 g and 80 g of the raw medicinal materials.
本发明所述的组合药物,采用低剂量的化学药物阿德福韦联合中药治疗急性病毒性肝炎的过程中,阿德福韦的用量小,耐药性小,对患者肾功能伤害较小,其中所用的中药大黄、连翘、白术、金钱草、半枝莲联合起到抗病毒的作用,甘草、郁金、覆盆子、玉米须起到保肝、增强免疫的作用。In the combined medicine of the present invention, in the process of treating acute viral hepatitis with low-dose chemical drug adefovir combined with traditional Chinese medicine, the dosage of adefovir is small, the drug resistance is small, and the damage to the patient's renal function is small. The traditional Chinese medicines rhubarb, forsythia, atractylodes macrocephala, desmodium, and barbatae combined play an antiviral effect, and licorice, turmeric, raspberry, and corn silk play a role in protecting the liver and enhancing immunity.
具体实施方式Detailed ways
以下结合具体实施例对本发明作进一步说明:The present invention will be further described below in conjunction with specific embodiment:
实施例1Example 1
按重量称取以下中药材:大黄150克、甘草150克、连翘150克、白术150克、金钱草150克、半枝莲150克、郁金150克、覆盆子150克、玉米须150克。Weigh the following Chinese medicinal materials by weight: 150 grams of rhubarb, 150 grams of licorice, 150 grams of forsythia, 150 grams of Atractylodes macrocephala, 150 grams of money grass, 150 grams of Scutellaria barbata, 150 grams of turmeric, 150 grams of raspberry, and 150 grams of corn silk .
按以下步骤制备:Prepare as follows:
(1)将原料药材,用14L的80%乙醇回流提取,提取2小时,过滤,药渣保留,收集乙醇提取液,减压回收乙醇后,进一步浓缩至稠膏,真空或微波干燥,得到干浸膏;(1) The raw medicinal materials are extracted with 14L of 80% ethanol under reflux, extracted for 2 hours, filtered, the dregs are retained, the ethanol extract is collected, and after the ethanol is recovered under reduced pressure, it is further concentrated to a thick paste, vacuum or microwave dried, and dried extract;
(2)将(1)步骤中保留的药渣加12L的水煎煮提取2次,每次2小时,过滤,合并水提液,减压浓缩至稠膏,真空干燥,得到干浸膏;(2) decocting and extracting the medicinal dregs retained in step (1) with 12 L of water twice, each time for 2 hours, filtering, combining the water extracts, concentrating under reduced pressure to a thick paste, and drying in vacuum to obtain a dry extract;
(3)将(1)和(2)步骤中所得的浸膏合并,粉碎,加入阿德福韦0.1克,加入淀粉至总重量为300g,混合均匀,制成颗粒,分装即得。(3) Combine the extracts obtained in steps (1) and (2), crush them, add 0.1 g of adefovir, add starch to a total weight of 300 g, mix evenly, make granules, and pack them separately.
实施例2Example 2
按重量称取以下中药材:大黄200克、甘草200克、连翘200克、白术200克、金钱草200克、半枝莲200克、郁金200克、覆盆子200克、玉米须200克。Weigh the following Chinese medicinal materials by weight: 200 grams rhubarb, 200 grams licorice, 200 grams forsythia, 200 grams Atractylodes macrocephala, 200 grams desmodium, 200 grams barbata, 200 grams turmeric, 200 grams raspberry, 200 grams corn silk .
按以下步骤制备:Prepare as follows:
(1)将原料药材,用18L的80%乙醇回流提取,提取2小时,过滤,药渣保留,收集乙醇提取液,减压回收乙醇后,进一步浓缩至稠膏,真空或微波干燥,得到干浸膏;(1) The raw medicinal materials are extracted with 18L of 80% ethanol under reflux, extracted for 2 hours, filtered, the dregs are retained, the ethanol extract is collected, and after the ethanol is recovered under reduced pressure, it is further concentrated to a thick paste, vacuum or microwave dried, and dried extract;
(2)将(1)步骤中保留的药渣加15L的水煎煮提取2次,每次2小时,过滤,合并水提液,减压浓缩至稠膏,真空干燥,得到干浸膏;(2) decocting and extracting the medicinal dregs retained in step (1) with 15 L of water twice, each time for 2 hours, filtering, combining the water extracts, concentrating under reduced pressure to a thick paste, and drying in vacuum to obtain a dry extract;
(3)将(1)和(2)步骤中所得的浸膏合并,粉碎,加入阿德福韦0.2克,加入淀粉至总重量为300g,混合均匀,制成颗粒,分装即得。(3) Combine the extracts obtained in steps (1) and (2), crush them, add 0.2 g of adefovir, add starch to a total weight of 300 g, mix evenly, make granules, and pack them separately.
实施例3Example 3
按重量称取以下中药材:大黄180克、甘草180克、连翘180克、白术180克、金钱草180克、半枝莲180克、郁金180克、覆盆子180克、玉米须180克。Weigh the following Chinese medicinal materials by weight: 180 grams of rhubarb, 180 grams of licorice, 180 grams of forsythia, 180 grams of Atractylodes macrocephala, 180 grams of money grass, 180 grams of Scutellaria barbata, 180 grams of turmeric, 180 grams of raspberry, 180 grams of corn silk .
按以下步骤制备:Prepare as follows:
(1)将原料药材,用16L的80%乙醇回流提取,提取2小时,过滤,药渣保留,收集乙醇提取液,减压回收乙醇后,进一步浓缩至稠膏,真空或微波干燥,得到干浸膏;(1) The raw medicinal materials are extracted with 16L of 80% ethanol under reflux, extracted for 2 hours, filtered, the dregs are retained, the ethanol extract is collected, and after the ethanol is recovered under reduced pressure, it is further concentrated to a thick paste, vacuum or microwave dried, and dried extract;
(2)将(1)步骤中保留的药渣加13L的水煎煮提取2次,每次2小时,过滤,合并水提液,减压浓缩至稠膏,真空干燥,得到干浸膏;(2) decocting and extracting the medicinal residues retained in step (1) with 13 L of water twice, each time for 2 hours, filtering, combining the water extracts, concentrating under reduced pressure to a thick paste, and vacuum drying to obtain a dry extract;
(3)将(1)和(2)步骤中所得的浸膏合并,粉碎,加入阿德福韦0.16克加入淀粉至总重量为300g,混合均匀,制成颗粒,分装即得。(3) Combine the extracts obtained in steps (1) and (2), crush them, add 0.16 g of adefovir, add starch to a total weight of 300 g, mix evenly, make granules, and pack them separately.
Claims (2)
- It is 1. a kind of for treating the composition of medicine of acute viral hepatitis, which is characterized in that the component of the composition of medicine be with Lower raw material medicaments in part by weight composition:0.01-0.02 parts of adefovirdipivoxil, 15-20 parts of rheum officinale, 15-20 parts of Radix Glycyrrhizae, 15-20 parts of Fructus Forsythiae, 15-20 parts of Rhizoma Atractylodis Macrocephalae, 15-20 parts of desmodium, 15-20 parts of Sculellaria barbata, 15-20 parts of Radix Curcumae, 15-20 parts of raspberry, corn stigma 15-20 Part;Preparation method includes the following steps:(1) by weight, it by raw materials of traditional Chinese medicinal materials, is extracted, extracted 2 hours with 80% alcohol reflux of 10 times of amounts, filtering, the dregs of a decoction Retain, collect ethanol extract, after ethyl alcohol is recovered under reduced pressure, be further concentrated into thick paste, vacuum or microwave drying, obtain dry leaching Cream;(2) dregs of a decoction retained in (1) step are added to the water boiling and extraction 2 times of 8 times of amounts, 1.5~2 hours every time, filtering merged water Extract is concentrated under reduced pressure into thick paste, vacuum or microwave drying, obtains dry extract;(3) dry extract of gained in (1) and (2) step is merged, crushed, added in adefovirdipivoxil, add starch or dextrin mixes It closes uniformly, tablet, particle or capsule is made, dispenses to obtain the final product.
- 2. the composition of medicine according to claim 1 for being used to treat acute viral hepatitis, which is characterized in that the combination The component of drug is formed for following raw material medicaments in part by weight:0.01 part of adefovirdipivoxil, 18 parts of rheum officinale, 18 parts of Radix Glycyrrhizae, 18 parts of Fructus Forsythiae, 18 parts of Rhizoma Atractylodis Macrocephalae, 18 parts of desmodium, 18 parts of Sculellaria barbata, 18 parts of Radix Curcumae, 18 parts of raspberry, 18 parts of corn stigma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510137276.9A CN104758827B (en) | 2015-03-26 | 2015-03-26 | A kind of composition of medicine for being used to treat acute viral hepatitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510137276.9A CN104758827B (en) | 2015-03-26 | 2015-03-26 | A kind of composition of medicine for being used to treat acute viral hepatitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104758827A CN104758827A (en) | 2015-07-08 |
CN104758827B true CN104758827B (en) | 2018-06-19 |
Family
ID=53641143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510137276.9A Expired - Fee Related CN104758827B (en) | 2015-03-26 | 2015-03-26 | A kind of composition of medicine for being used to treat acute viral hepatitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104758827B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI654985B (en) * | 2017-09-04 | 2019-04-01 | 漢聖製藥科技股份有限公司 | Use of extract of Antrodia camphorata fruit complex wine for preparing medicine for treating hepatitis B |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1611260A (en) * | 2003-11-01 | 2005-05-04 | 杨喜鸿 | Combined medicine of adefovir dipivoxil |
CN103099823A (en) * | 2011-11-11 | 2013-05-15 | 刘毅佳 | Anti-hepatitis B pharmaceutical composition and its preparation method and use |
-
2015
- 2015-03-26 CN CN201510137276.9A patent/CN104758827B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1611260A (en) * | 2003-11-01 | 2005-05-04 | 杨喜鸿 | Combined medicine of adefovir dipivoxil |
CN103099823A (en) * | 2011-11-11 | 2013-05-15 | 刘毅佳 | Anti-hepatitis B pharmaceutical composition and its preparation method and use |
Non-Patent Citations (3)
Title |
---|
中西医结合救治重症黄疽型肝炎21例;马安荣等;《中国中医药科技》;19970615;第4卷(第3期);第189页左边栏第2、3段,右边栏第4段、第190页左边栏第1-2段 * |
急性病毒性肝炎的用药体会;肖袁柳等;《内蒙古中医药》;20101130(第22期);第56页左边栏第2段,右边栏第2段 * |
病毒性肝炎治验摘介( 一);梁映寰;《新中医》;19870131(第01期);第21-25页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104758827A (en) | 2015-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102488850B (en) | Traditional Chinese medicinal composition for treating alcoholic fatty liver and preparation method thereof | |
JP2004530634A (en) | Novel pharmaceutical herbal composition for treating liver disease and HIV | |
JP2004537508A (en) | Antitumor drug | |
CN102397372A (en) | Pharmaceutical composition, preparation and application of pharmaceutical composition in treating irritable bowel syndrome | |
CN102488879A (en) | Medicinal composition for treating rheumatism | |
CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
CN104758827B (en) | A kind of composition of medicine for being used to treat acute viral hepatitis | |
CN102671056B (en) | Chinese medicinal composition for treating hepatitis and preparation method thereof | |
CN104174005A (en) | Medicine for treating hepatitis b cirrhosis | |
CN114699498A (en) | Pharmaceutical composition for resisting chronic hepatitis B and application thereof | |
CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
CN104056234A (en) | Drug for dispelling alcohol effect and preparing method thereof | |
CN104758676A (en) | Medicine for treating damp-heat in resistance-type epigastric pain | |
CN111265554A (en) | Application of antiviral compound composition in anti-HIV virus, SARS virus and leukemia virus | |
CN104147270A (en) | Traditional Chinese medicine for treating acute hepatitis | |
CN117224624B (en) | Traditional Chinese medicine composition for preventing and/or treating renal edema and preparation method thereof | |
CN103705831B (en) | A kind of pharmaceutical composition treating menopausal syndrome and preparation method thereof | |
CN108186909A (en) | The Chinese medicine composition and its compound preparation of improvement insulin resistance syndrome and application | |
CN108079089B (en) | A kind of traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
CN106334158A (en) | Traditional Chinese medicine composition for treating virus hepatitis and preparation method thereof and application | |
CN105920539A (en) | Medicament for treating foot-and-mouth disease of sheep | |
CN105770188B (en) | liver-protecting traditional Chinese medicine preparation and preparation method thereof | |
CN103800875A (en) | Traditional Chinese medicine for treating chronic renal failure and preparation method thereof | |
CN118924819A (en) | A Chinese medicine formula for treating liver, kidney and other diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180619 Termination date: 20210326 |
|
CF01 | Termination of patent right due to non-payment of annual fee |